Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

GENELUX Corp (GNLX)

$2.89 -2.36% NASDAQ: GNLX · 15-min delayed
  • WESTLAKE VILLAGE, California
  • Public · NASDAQ: GNLX
  • 26 employees
  • Founded 2001
$131.4MMarket cap
$8.0KRevenue · FY2025
-$32.1MNet income
26Employees
GNLXNASDAQ
2023IPO

About GENELUX Corp

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$8.0K
Net income
-$32.1M
Total assets
$19.0M
Market cap
$131.4M
Operating margin
-415175.0%
Net margin
-401812.5%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$8.0K
Operating expenses
$33.2M
Operating income
-$33.2M
Net income
-$32.1M
EPS (basic)
$-0.86
EPS (diluted)
$-0.86

Balance sheet

Total assets
$19.0M
Current assets
$15.1M
Total liabilities
$7.5M
Current liabilities
$6.2M
Shareholders’ equity
$11.5M

Cash flow

Operating cash flow
-$25.3M
Investing cash flow
$12.1M
Financing cash flow
$9.9M
Net cash flow
-$3.2M

Statements via Polygon.io (SEC filings)

NASDAQ: GNLX
$2.89 -2.36%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.30 $8.24

52-week range

Market cap
$131.4M
EPS (diluted)
$-0.86
Shares outstanding
45.5M
Open
Day range
Prev close
Volume
IPO date
Jan 26, 2023

GENELUX Corp (GNLX) Stock Price

  • Reported a net loss of $32.1M in FY2025.
  • Revenue declined 95% from FY2023 to FY2025.
  • Trading 65% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review GENELUX Corp.

Write a review
Newsroom

News about GENELUX Corp

News & sentiment via Polygon.io

FAQ

GENELUX Corp: frequently asked questions

Is GENELUX Corp an American company?

GENELUX Corp is a US-based company headquartered in Westlake Village, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is GENELUX Corp headquartered?

GENELUX Corp is headquartered in Westlake Village, California, United States.

Is GENELUX Corp publicly traded?

Yes — GENELUX Corp is a publicly traded company. Its stock trades under the ticker symbol GNLX on the NASDAQ.

What does GENELUX Corp do?

GENELUX Corp is an American Pharmaceuticals company in the Health & Beauty sector.

When was GENELUX Corp founded?

GENELUX Corp was founded in 2001.

Explore

Similar companies

Browse all →